An Open-label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Trial Profile

An Open-label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs QR 110 (Primary)
  • Indications Leber congenital amaurosis
  • Focus Adverse reactions; First in man
  • Sponsors ProQR Therapeutics
  • Most Recent Events

    • 13 Nov 2017 According to a ProQR Therapeutics media release, the first patient has been dosed in this trial.
    • 09 Nov 2017 According to a ProQR Therapeutics media release, interim data are expected in 2018 and full data are expected 2019.
    • 21 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top